Compare Cassava Sciences Inc (FLNA) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs LyondellBasell Industries NV — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while LyondellBasell Industries NV trades at $57.88 (market cap $18.72B). The key difference: LyondellBasell Industries NV is far larger — about 352.3× Cassava Sciences Inc's market cap, and LyondellBasell Industries NV pays a 7.1% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LYB | |
|---|---|---|
Market Cap | $53.14M | $18.72B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $82.38 |
52-Week Low | $1.09 | $42.28 |
Enterprise Value | -$33.43M | $30.34B |
Dividend Yield | — | 7.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
LYB trades at $58.79, up 0.4% on the day, with a bullish technical signal and positive analyst consensus. The stock shows mixed fundamentals with declining revenue and negative net income margins, though recent earnings beats and strategic partnerships in sustainable packaging provide optimism. Cash flow remains positive, and the company maintains a dividend, supporting income-focused investors amid cyclical challenges.
Outlook is cautiously optimistic with a consensus price target of $73.11 implying 24% upside, but risks include persistent margin pressure, high debt, and industry headwinds. Investment appeal hinges on execution of cost-cutting and recycling initiatives, with volatility expected near Q2 earnings on July 31, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
